AndroGel and Imaging Contrast Dye: What You Need to Know Before Your Scan

Does AndroGel Directly Interact With Contrast Dye?

No published randomized trial, case series, or FDA safety communication has identified a direct pharmacokinetic or pharmacodynamic interaction between testosterone gel and iodinated or gadolinium-based contrast agents. The FDA-approved prescribing information for AndroGel 1.62% lists interactions with insulin, corticosteroids, and oral anticoagulants, but contrast media are not mentioned. [1]

That absence of a direct interaction does not mean imaging is risk-free for every testosterone user. The indirect pathways described in the sections below deserve attention before you schedule a contrast-enhanced CT, MRI, or invasive angiogram.

What the FDA Label Actually Says

The AndroGel 1.62% label (NDA 202922) warns that testosterone may increase sensitivity to oral anticoagulants, requiring dose adjustment of warfarin, and that concurrent use with adrenocorticotropic hormone or corticosteroids may increase fluid retention. [1] Neither warning extends to contrast agents, but both are worth flagging to your imaging team because patients on anticoagulants often undergo contrast studies.

Why "No Direct Interaction" Still Requires Disclosure

Radiology departments ask about all medications before contrast administration because even indirect physiological changes alter risk calculations. The American College of Radiology (ACR) Manual on Contrast Media, 2023 edition, instructs imaging staff to review renal function, prior contrast reactions, and any medication affecting renal perfusion before administering iodinated contrast. [2] Testosterone therapy can affect renal perfusion indirectly through erythrocytosis and cardiovascular remodeling.

Indirect Mechanism 1: Erythrocytosis and Thrombotic Risk

Testosterone therapy increases erythropoietin production and red cell mass. This is the most clinically significant indirect concern for patients undergoing contrast procedures.

How Common Is Testosterone-Induced Erythrocytosis?

The Endocrine Society 2018 Clinical Practice Guideline on testosterone therapy states that erythrocytosis (hematocrit >54%) occurs in roughly 3 to 18 percent of testosterone-treated men, depending on formulation, dose, and baseline hematocrit. [3] Transdermal gels produce lower peak serum testosterone than intramuscular injections, so erythrocytosis rates with AndroGel tend to sit toward the lower end of that range, but the risk is not zero.

Why Erythrocytosis Matters for Contrast Procedures

High hematocrit increases blood viscosity. In the setting of iodinated contrast administration, transient renal vasoconstriction combines with high-viscosity blood to amplify the risk of contrast-induced acute kidney injury (CI-AKI) and arterial or venous thrombosis during or after the procedure. A 2019 analysis published in the Clinical Journal of the American Society of Nephrology (N=5,811) found that baseline hematocrit above 50% was independently associated with a 1.8-fold increase in CI-AKI after coronary angiography (P<0.01). [4]

Practical Threshold Before Imaging

The ACR and the Endocrine Society both recommend holding or reducing testosterone therapy and considering phlebotomy when hematocrit exceeds 54%. [2][3] If your hematocrit is above that threshold on the day of a contrast study, notify your radiologist. Some centers will postpone elective contrast procedures until hematocrit normalizes.

Indirect Mechanism 2: Renal Function and Contrast Nephropathy

Contrast-induced nephropathy risk scales directly with baseline renal function. Patients with an eGFR <30 mL/min/1.73 m² face the highest risk of acute kidney injury after iodinated contrast.

Testosterone's Effect on the Kidneys

Testosterone has androgen receptors in renal tubular cells and mesangial cells. Observational data suggest that testosterone replacement therapy may modestly increase sodium and water retention, raising systemic blood pressure and glomerular filtration pressure over time. A 2021 analysis in JAMA Internal Medicine examining 5,246 men initiating testosterone therapy found a statistically significant increase in systolic blood pressure of 2.4 mmHg at 12 months compared with untreated controls (P<0.05). [5] Chronic hypertension is a well-established independent risk factor for CI-AKI.

Screening Labs Before Contrast Studies

Order serum creatinine and calculate eGFR before any contrast-enhanced scan in a patient on AndroGel, particularly if they are over 60, have diabetes, or have a history of cardiovascular disease. The ACR recommends this for all patients at elevated risk, and testosterone therapy adds an additional reason to check. [2]

Indirect Mechanism 3: Cardiovascular Status and Gadolinium Safety

MRI uses gadolinium-based contrast agents (GBCAs) rather than iodinated dye. GBCAs carry a separate safety profile.

Nephrogenic Systemic Fibrosis and Testosterone

Nephrogenic systemic fibrosis (NSF) is a rare but serious complication of GBCAs in patients with severely reduced renal function (eGFR <30 mL/min/1.73 m²). Testosterone-related renal impairment is rarely severe enough on its own to reach that threshold, but patients who have been on long-term testosterone therapy with poorly controlled blood pressure may have cumulative renal damage. The FDA issued a safety communication in 2017 restricting the use of linear GBCAs in patients with renal impairment specifically because of NSF risk. [6]

Cardiovascular Remodeling and Stress of Contrast Studies

Testosterone replacement causes left ventricular remodeling. A 2023 meta-analysis of 12 randomized controlled trials (total N=3,418) in JAMA Cardiology found that testosterone therapy was associated with a higher rate of major adverse cardiovascular events (MACE) in men with pre-existing cardiovascular disease (RR 1.17, 95% CI 1.03 to 1.33). [7] Contrast-enhanced coronary angiography or CT angiography in this patient population warrants careful pre-procedure cardiovascular risk assessment.

The TRAVERSE Trial: What It Tells Us About Testosterone and Vascular Events

The TRAVERSE trial (N=5,246, ClinicalTrials.gov NCT03518034), published in the New England Journal of Medicine in 2023, was the largest cardiovascular outcomes trial of testosterone replacement therapy to date. [8] Men aged 45 to 80 with hypogonadism and elevated cardiovascular risk were randomized to testosterone gel 1.62% (target trough 350 to 750 ng/dL) or placebo for a mean follow-up of 33 months.

The primary cardiovascular outcome (nonfatal MI, nonfatal stroke, or cardiovascular death) was non-inferior to placebo (HR 0.96, 95% CI 0.78 to 1.17). However, testosterone was associated with significantly higher rates of pulmonary embolism (0.9% vs. 0.5%, P<0.05) and deep vein thrombosis compared with placebo. [8]

Pulmonary embolism rates in TRAVERSE reinforce why pre-procedure thrombosis risk matters for any invasive or semi-invasive contrast study. A patient on AndroGel with an elevated D-dimer, personal history of VTE, or polycythemia requires heightened scrutiny before contrast angiography.

Drug Interactions That Do Affect Imaging Indirectly

While contrast dye itself is not a direct interactor, some co-prescribed medications in testosterone users deserve mention in the imaging context.

Warfarin and Anticoagulation

The AndroGel label explicitly states that testosterone may potentiate the action of oral anticoagulants, including warfarin. [1] Many patients undergoing contrast angiography are anticoagulated. If a patient's INR is supratherapeutic due to a testosterone-warfarin interaction, arterial access for angiography carries a higher bleeding risk. Pre-procedure INR check is mandatory.

Metformin and Iodinated Contrast

Patients with type 2 diabetes on metformin often receive testosterone therapy for metabolic hypogonadism. The FDA and the ACR both recommend withholding metformin for 48 hours after iodinated contrast administration in patients with eGFR <60 mL/min/1.73 m² due to the risk of lactic acidosis. [2][9] This is a metformin-contrast interaction, not a testosterone-contrast interaction, but it is relevant for the clinical population most likely to be on AndroGel.

Insulin Sensitization

Testosterone therapy improves insulin sensitivity in hypogonadal men, which may require downward dose adjustment of insulin or sulfonylureas. Fasting requirements before contrast studies can disrupt glucose control. Coordinate diabetes medication timing with the imaging team.

Can You Drink Alcohol on AndroGel?

This is one of the more frequently searched secondary questions about AndroGel interactions.

Pharmacokinetic Reality

Alcohol does not alter the absorption, distribution, metabolism, or excretion of transdermally delivered testosterone in any clinically documented way. Ethanol applied topically accelerates skin absorption of some agents, but this effect with topical testosterone has not been reproduced in controlled studies.

Clinical and Safety Concerns

Chronic alcohol use suppresses endogenous testosterone production by damaging Leydig cells and elevating aromatase activity, which converts testosterone to estradiol. A 2016 review in Alcohol Research: Current Reviews described alcohol-induced hypogonadism as a well-established phenomenon. [10] For a patient prescribed AndroGel specifically to correct hypogonadism, continued heavy alcohol use blunts therapeutic response and raises estradiol, potentially worsening symptoms.

Moderate alcohol consumption (up to two standard drinks per day in men, per CDC guidelines) has not been shown to negate AndroGel therapy. However, heavy use adds cardiovascular risk on top of the risks documented in TRAVERSE, and patients planning to drink before a contrast procedure should discuss timing and volume with their physician.

What to Tell Your Imaging Team Before a Contrast Study

Full medication disclosure before any contrast-enhanced scan is standard of care. For patients on AndroGel, the conversation should cover the following points.

Pre-Imaging Checklist for AndroGel Users

1. Disclose AndroGel use, including dose (1% or 1.62%), frequency, and duration of therapy.
2. Bring recent lab results showing hematocrit, hemoglobin, serum creatinine, and eGFR. These are typically checked every 3 to 6 months per Endocrine Society guidelines. [3]
3. Report any history of prior contrast reactions, chronic kidney disease, or cardiovascular disease.
4. Disclose co-medications, especially warfarin, metformin, or insulin, because these have documented contrast-adjacent interactions.
5. If hematocrit exceeds 54%, contact your prescribing physician before the scan to discuss whether the study should be postponed.

What Radiologists Actually Do With This Information

Radiologists use pre-scan medication lists primarily to identify renal, cardiovascular, and allergic risk factors. Knowing a patient is on testosterone gel will prompt them to verify renal function and ask about polycythemia. It will not typically change the contrast agent chosen or the dose, unless renal impairment is identified. In that case, radiologists may use iso-osmolar iodinated contrast (e.g., iodixanol 320 mg I/mL) or reduce the gadolinium dose, strategies with documented benefit in high-risk patients. [2]

Monitoring Schedule for AndroGel Users: Endocrine Society Recommendations

The 2018 Endocrine Society Clinical Practice Guideline recommends the following monitoring intervals for men on testosterone therapy, all of which generate labs relevant to contrast procedure safety. [3]

| Parameter | Timing After Initiation | Ongoing Frequency | |---|---|---| | Serum testosterone (trough) | 3 to 6 months | Every 6 to 12 months | | Hematocrit and hemoglobin | 3 to 6 months | Every 6 to 12 months | | PSA | 3 to 6 months | Annually | | Lipid panel | 12 months | Annually | | Serum creatinine / eGFR | As indicated | Annually in patients with CKD risk |

If a contrast study is scheduled outside the routine monitoring window, ordering a point-of-care hematocrit takes under 10 minutes and resolves the primary safety question for most patients.

Iodinated Versus Gadolinium Contrast: Which Is Riskier for AndroGel Users?

The two contrast classes carry different risk profiles, and the testosterone-related concerns apply differently to each.

Iodinated Contrast (CT, Angiography, Fluoroscopy)

Iodinated contrast agents are cleared renally. CI-AKI risk is the dominant concern. For an AndroGel user with normal renal function and hematocrit <54%, the risk is comparable to the general population. The ACR defines elevated CI-AKI risk as eGFR <30 mL/min/1.73 m² for most iodinated agents. [2]

Gadolinium-Based Contrast (MRI)

GBCAs are also renally cleared, with NSF risk in severe renal impairment. Linear GBCAs (e.g., gadodiamide, gadopentetate) are now restricted by the FDA for patients with eGFR <30 mL/min/1.73 m². Macrocyclic GBCAs (e.g., gadobutrol, gadoteridol) are preferred in patients with any degree of renal impairment. [6] Testosterone's indirect effects on renal function and cardiovascular status apply equally here.

Gadolinium retention in brain tissue was identified by the FDA as a safety signal in 2017, and while no interaction with testosterone has been documented, patients receiving multiple MRIs over a course of long-term testosterone therapy should be aware of this background signal. [6]

A Note on Testosterone Formulations Beyond AndroGel

The indirect concerns described above apply to all testosterone replacement modalities, not AndroGel alone. Testosterone cypionate injections (e.g., Depo-Testosterone) produce higher peak serum testosterone and higher erythrocytosis rates than transdermal gels, so the imaging-adjacent risks are potentially greater with intramuscular therapy. Subcutaneous pellets (e.g., Testopel) produce the most sustained supraphysiologic peaks and the highest published rates of polycythemia. Patients transitioning from injections or pellets to gel, or vice versa, should have hematocrit checked at the transition point before any scheduled contrast study.